Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00369837
Status:
COMPLETED
Last Update Posted:
2014-05-22
First Post:
2006-08-25
Brief Title:
Clevidipine in the Treatment of Patients With Severe Hypertension VELOCITY
Sponsor:
The Medicines Company
Organization:
The Medicines Company
Study Overview
Official Title:
Evaluation of the Effect of Ultrashort-Acting Clevidipine in the Treatment of Patients With Severe Hypertension VELOCITY
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VELOCITY
Brief Summary:
The purpose of this study was to determine the safety of clevidipine for treating severely elevated blood pressure defined as systolic SBP 180 mmHg andor diastolic blood pressure DBP 115 mmHg assessed on 2 successive occasions 15 minutes apart at baseline in patients with or without major organ injury particularly with respect to controlled dose adjustment to desired effect and prolonged continuous infusion Enrollment of patients into the study was to continue until the target goal of 100 patients with at least 18 hours of continuous clevidipine treatment including a minimum of 50 patients with acute or chronic end-organ injury was met
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| VELOCITY | OTHER | Sponsor | None |